Grail Shares Plunge as Galleri Cancer Test Misses Trial Goal

Following the announcement, Grail’s stock plummeted 47% to $54.20 in after-hours trading, a sharp reversal for a ticker that had surged 93% over the previous year. The trial focused on participants aged 50 to 77 to determine if annual screening could justify a national rollout in England. While the test failed to achieve a statistically significant reduction in overall Stage III and Stage IV cancers, the company pointed to specific successes within the data.

Trends in Early Detection

According to the report, the trial showed a favorable trend toward fewer late-stage diagnoses in a subset of 12 high-mortality cancers. Grail noted that Stage IV diagnoses in these specific cases decreased with each year of sequential screening, showing a reduction of more than 20% by the second and third rounds. These findings suggest that while the primary goal was missed, the technology may still influence how aggressive diseases are caught in their earlier stages.

Chief Executive Bob Ragusa stated that the trial provides the strongest evidence yet that multi-cancer early detection can shift the stage of diagnosis at a population level. Despite this optimism, the failure to meet the primary endpoint creates uncertainty for the test's immediate adoption by the NHS. The company had hoped the results would secure a permanent place for Galleri within the UK’s national screening infrastructure.